Skip to main content

Advertisement

SpringerLink
Log in

SATB2 suppresses non-small cell lung cancer invasiveness by G9a

  • Original Article
  • Published:
Clinical and Experimental Medicine Aims and scope Submit manuscript

Abstract

Special AT-rich sequence-binding protein 2 (SATB2) is a transcription factor, which plays an important role in transcriptional regulation and chromatin recombinant by combining with matrix attachment regions. More evidence shows that SATB2 is involved in progression of breast cancer, head and neck squamous cell carcinomas and osteosarcoma. However, the role of SATB2 in cancer initiation and progression is still not well understood. Our study identified that decreased expression of SATB2 was correlated with tumor progression and poor prognosis in non-small cell lung cancer (NSCLC) patients. Furthermore, SATB2 suppressed lung cancer cell invasion and metastasis and regulated the expression of EMT-related proteins and histone methylation by G9a. In summary, SATB2 may act as a tumor suppressor gene in NSCLC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

Abbreviations

SATB2:

Special AT-rich sequence-binding protein 2

MARs:

Matrix attachment regions

NSCLC:

Non-small cell lung cancer

EMT:

Epithelial to mesenchymal transition

HMT:

Histone lysine methyltransferase

HNSCC:

Head and neck squamous cell carcinoma

References

  1. Dobreva G, Dambacher J, Grosschedl R. SUMO modification of a novel MAR-binding protein, SATB2, modulates immunoglobulin mu gene expression. Genes Dev. 2003;17:3048–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Cai S, Lee CC, Kohwi-Shigematsu T. SATB1 packages densely looped, transcriptionally active chromatin for coordinated expression of cytokine genes. Nat Genet. 2006;38:1278–88.

    Article  CAS  PubMed  Google Scholar 

  3. Dobreva G, Chahrour M, Dautzenberg M, et al. SATB2 is a multifunctional determinant of craniofacial patterning and osteoblast differentiation. Cell. 2006;125:971–86.

    Article  CAS  PubMed  Google Scholar 

  4. Britanova O, Akopov S, Lukyanov S, et al. Novel transcription factor Satb2 interacts with matrix attachment region DNA elements in a tissue-specific manner and demonstrates cell-type-dependent expression in the developing mouse CNS. Eur J Neurosci. 2005;21:658–68.

    Article  PubMed  Google Scholar 

  5. Gyorgy AB, Szemes M, de Juan Romero C, et al. SATB2 interacts with chromatin-remodeling molecules in differentiating cortical neurons. Eur J Neurosci. 2008;27:865–73.

    Article  PubMed  Google Scholar 

  6. Notani D, Gottimukkala KP, Jayani RS, et al. Global regulator SATB1 recruits β-catenin and regulates T(H)2 differentiation in Wnt-dependent manner. PLoS Biol. 2010;8:e1000296.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Britanova O, de Juan Romero C, Cheung A, et al. Satb2 is a postmitotic determinant for upper-layer neuron specification in the neocortex. Neuron. 2008;57(3):378–92.

    Article  CAS  PubMed  Google Scholar 

  8. Zhao X, Qub Z, et al. The role of SATB2 in skeletogenesis and human disease. Cytokine Growth Factor Rev. 2014;25(1):35–44.

    Article  CAS  PubMed  Google Scholar 

  9. Patani N, Jiang W, Mansel R, et al. The mRNA expression of SATB1 and SATB2 in human breast cancer. Cancer Cell Int. 2009;9:18.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Chung J, Lau J, Cheng LS, et al. SATB2 augments DeltaNp63alpha in head and neck squamous cell carcinoma. EMBO Rep. 2010;11(10):777–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Wang S, Zhou J, Wang XY, et al. Down-regulated expression of SATB2 is associated with metastasis and poor prognosis in colorectal cancer. J Pathol. 2009;219(1):114–22.

    Article  CAS  PubMed  Google Scholar 

  12. Mansour MA, Asano E, Hyodo T, et al. Special AT-rich sequence-binding protein 2 suppresses invadopodia formation in HCT116 cells via palladin inhibition. Exp Cell Res. 2015;332(1):78–88.

    Article  CAS  PubMed  Google Scholar 

  13. Yang MH, Yu J, Jiang DM, et al. microRNA-182 targets special AT-rich sequence-binding protein 2 to promote colorectal cancer proliferation and metastasis. J Trans Med. 2014;12:109.

    Article  Google Scholar 

  14. Yang MH, Yu J, Chen N, et al. Elevated microRNA-31 expression regulates colorectal cancer progression by repressing its target gene SATB2. PLoS ONE. 2013;8(12):e85353.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Wu L, Chen J, Qin Y, et al. SATB2 suppresses gastric cancer cell proliferation and migration. Tumour Biol. 2016;37(4):4597–602.

    Article  CAS  PubMed  Google Scholar 

  16. Thiery JP, Acloque H, Huang RY, et al. Epithelial-mesenchymal transitions in development and disease. Cell. 2009;139(5):871–90.

    Article  CAS  PubMed  Google Scholar 

  17. Otsuki T, Fujimoto D, Hirono Y, et al. Thrombin conducts epithelial–mesenchymal transition via protease-activated receptor-1 in human gastriccancer. Int J Oncol. 2014;45(6):2287–94.

    Article  CAS  PubMed  Google Scholar 

  18. Wei J, Shi Y, Zheng L, et al. miR-34 s inhibit osteoblast proliferation and differentiation in the mouse by targeting SATB2. J Cell Biol. 2012;197(4):509–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Casciello F, Windloch K, Gannon F, et al. Functional role of G9a histone methyltransferase in cancer. Front Immunol. 2015;6:487.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Chen MW, Hua KT, Kao HJ, et al. H3K9 histone methyltransferase G9a promotes lung cancer invasion and metastasis by silencing the cell adhesion molecule Ep-CAM. Cancer Res. 2010;70(20):7830–40.

    Article  CAS  PubMed  Google Scholar 

  21. Huang J, Dorsey J, Chuikov S, et al. G9a and Glp methylate lysine 373 in the tumor suppressor p53. J Biol Chem. 2010;285(13):9636–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Zhong X, Chen X, Guan X, et al. Overexpression of G9a and MCM7 in oesophageal squamous cell carcinoma is associated with poor prognosis. Histopathology. 2015;66(2):192–200.

    Article  PubMed  Google Scholar 

  23. Wozniak RJ, Klimecki WT, Lau SS, et al. 5-Aza-2′-deoxycytidine-mediated reductions in G9A histone methyltransferase and histone H3 K9 di-methylation levels are linked to tumor suppressor gene reactivation. Oncogene. 2007;26(1):77–90.

    Article  CAS  PubMed  Google Scholar 

  24. Poggi A, Giuliani M. Mesenchymal stromal cells can regulate the immune response in the tumor microenvironment. Vaccines Basel. 2016;4(4):41.

    Article  PubMed Central  Google Scholar 

  25. Dong C, Wu Y, Yao J, et al. G9a interacts with Snail and is critical for Snail-mediated E-cadherin repression in human breast cancer. J Clin Invest. 2012;122(4):1469–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Mansour MA, Hyodo T, Ito S, Kurita K, et al. SATB2 suppresses the progression of colorectal cancer cells via inactivation of MEK5/ERK5 signaling. FEBS J. 2015;282(8):1394–405.

    Article  CAS  PubMed  Google Scholar 

  27. Wu L, Chen J, Qin Y, Mo X, Huang M, Ru H, et al. SATB2 suppresses gastriccancer cell proliferation and migration. Tumour Biol Tumour Biol. 2016;37(4):4597–602.

    Article  CAS  PubMed  Google Scholar 

  28. Seong BK, Lau J, Adderley T, Kee L, et al. SATB2 enhances migration and invasion in osteosarcoma by regulating genes involved in cytoskeletal organization. Oncogene. 2015;34(27):3582–92.

    Article  CAS  PubMed  Google Scholar 

  29. Kucuksayana H, Ozesb ON, Akcaa H. Downregulation of SATB2 is critical for induction of epithelial-to-mesenchymal transition and invasion of NSCLC cells. Lung Cancer. 2016;98:122–9.

    Article  Google Scholar 

  30. Mansour MA, Hyodo T, Akter KA, et al. SATB1 and SATB2 play opposing roles in c-Myc expression and progression of colorectal cancer. Oncotarget. 2016;7(4):4993–5006.

    Article  PubMed  Google Scholar 

  31. Estève PO, Chin HG, Smallwood A, et al. Direct interaction between DNMT1 and G9a coordinates DNA and histone methylation during replication. Genes Dev. 2006;20(22):3089–103.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6(269):l1.

    Article  Google Scholar 

  33. Lehnertz B, Pabst C, Su L, et al. The methyltransferase G9a regulates HoxA9-dependent transcription in AML. Genes Dev. 2014;28(4):317–27.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Hua KT, Wang MY, Chen MW, et al. The H3K9 methyltransferase G9a is a marker of aggressive ovarian cancer that promotes peritoneal metastasis. Mol Cancer. 2014;13:189.

    Article  PubMed  PubMed Central  Google Scholar 

  35. FitzPatrick DR, Carr IM, McLaren L, et al. Identification of SATB2 as the cleft palate gene on 2q32–q33. Hum Mol Genet. 2003;12:2491–501.

    Article  CAS  PubMed  Google Scholar 

  36. Bengani H, Handley M, Alvi M, et al. Clinical and molecular consequences of disease-associated de novo mutations in SATB2. Genet Med. 2017. doi:10.1038/gim.2016.211.

    PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

We thank Yu-chen Han, Yi-nan Ma and Hai-yan Zhang for their constructive comments and suggestions on the manuscript, Liang-Ru Fei, Mei-Yu Zhang, Cong-Cong Wang and Yuan Luo for technical support. Yinan Ma takes responsibility for the integrity of the article. We also thank National Natural Science Foundation of China (No. 81272605) for supporting this study.

Author information

Author notes

  1. Yi-nan Ma and Hai-Yan Zhang have contributed equally to the work.

Authors and Affiliations

  1. Departments of Pathology, First Affiliated Hospital of China Medical University, No. 155 Nanjing Road, Heping District, Shenyang, Liaoning Province, People’s Republic of China

    Yi-nan Ma, Cong-Cong Wang & Yu-Chen Han

  2. Departments of Pathology, School of Basic Medical Sciences, China Medical University, Shenyang, People’s Republic of China

    Liang-Ru Fei, Mei-Yu Zhang, Yuan Luo & Yu-Chen Han

  3. Departments of Pathology, First People’s Hospital of Jining, Shandong, People’s Republic of China

    Hai-Yan Zhang

Authors
  1. Yi-nan Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hai-Yan Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Liang-Ru Fei
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mei-Yu Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Cong-Cong Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yuan Luo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yu-Chen Han
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yu-Chen Han.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

The study protocol conforms to the ethical guidelines of the World Medical Association, Declaration of Helsinki—Ethical Principles for Medical Research Involving Human Subjects adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964, and amended by the 64th WMA General Assembly, Fortaleza, Brazil, October 2013, as reflected in a priori approval by the appropriate institutional review committee. The Hospital General Universitario Ethic’s Committee approved the protocol, and all patients gave their informed consent for the inclusion in the study.

Informed consent

Informed consent was obtained from each patient on the day of admission.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ma, Yn., Zhang, HY., Fei, LR. et al. SATB2 suppresses non-small cell lung cancer invasiveness by G9a. Clin Exp Med 18, 37–44 (2018). https://doi.org/10.1007/s10238-017-0464-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10238-017-0464-3

Keywords

Search

Navigation